[1] No authors listed.Guidelines for referral and management of systemic lupus erythematosus in adults.American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.Arthritis Rheum,1999,42:1785-1796. [2] 郑敏,朱铁城.SLE患者B淋巴细胞增殖功能测定及其临床意义.中华皮肤科杂志,1990,23:90-92. [3] Bombardier C,Gladman DD,Urowitz MB,et al.Derivation of the SLEDAI.A disease activity index for lupus patients.The Committee on Prognosis Studies in SLE.Arthritis Rheum,1992,35:630-640. [4] Blom T,Franzen A,Heinegard D,et al.Comment on "The influence of the proinflammatory cytokine,osteopontin,on autoimmune demyelinating disease".Science,2003,299:1845. [5] Ashkar S,Weber GF,Panoutsakopoulou V,et al.Eta-1 (osteopontin):an early component of type-1 (cell-mediated) immunity.Science,2000,287:860-864. [6] Hartner A,Porst M,Gauer S,et al.Glomerular osteopontin expression and macrophage infiltration in glomerulosclerosis of DOCA-salt rats.Am J Kidney Dis,2001,38:153-164. [7] Aringer M,Smolen JS.Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus:a rationale for therapeutic intervention.Lupus,2004,13:344-347. [8] Masutani K,Akahoshi M,Tsuruya K,et al.Predominance of Thlimmune response in diffuse proliferative lupus nephritis.Arthritis Rheum,2001,44:2097-2106. |